To include your compound in the COVID-19 Resource Center, submit it here.

Verastem’s value play

How Verastem parlayed duvelisib deal into a $54 million market cap bump

Verastem Inc. (NASDAQ:VSTM) has parlayed a small gamble on Phase III asset duvelisib into a double-digit stock bump and what could become the company’s first commercial product.

Verastem soared $1.08 (28%) to $4.92 on Sept. 6, adding $40 million in market cap,

Read the full 412 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE